Elektrofi
Gabriel Lind is a Senior Research Associate at Elektrofi since June 2023, leading the development and qualification of novel methods for the identification and characterization of small volume particles (SVPs) and vesicles (VPs) in samples, while also authoring and revising standard operating procedures (SOPs) related to these methods. Previously, Gabriel worked as a Research Associate at Elektrofi, contributing to the Analytical Development team by writing SOPs and technical reports, generating and qualifying new procedures, and running samples. Gabriel's earlier experience includes an Analytical Development Co-op at Elektrofi, where work focused on HPLC techniques and the development of a new analytical technique using microscopy. At Harvard Medical School, Gabriel contributed to research on Huntington's Disease by generating nuclear RNA profiles on brain tissue samples and optimizing gene amplification methods. Gabriel holds a Bachelor's degree in Honors Chemical Engineering and Biochemistry from Northeastern University.
This person is not in any teams
This person is not in any offices
Elektrofi
1 followers
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company’s founding team of MIT engineers and scientists are shaping the future of biologics delivery.